İpek Merve EVRÜKE, İnci Sema TAŞ

Premenopozal ve postmenopozal kadınlarda urge üriner inkontinans için kullanılan solifenasinin cinsel fonksiyon üzerine etkisi: prospektif gözlemsel bir çalışma

Amaç: Bu çalışmanın amacı urge üriner inkontinans tedavisinde kullanılan solifenasinin cinsel fonksiyonlarda iyileşme sağlayıp sağlamadığını değerlendirmek ve eğer düzelme var ise bunun premenopozal ve postmenopozal kadınlar arasında farklılık gösterip göstermediğini belirlemektir. Gereç ve Yöntem: 48 premenopozal ve 72 postmenopozal olmak üzere 120 kadın hasta çalışmaya dahil edilmiştir. Hastalar urge üriner inkontinans nedenli başlanan 5 mg/gün solifenasin tedavisinden önce ve tedaviden üç ay ve altı ay sonra Kadın Cinsel İşlev İndeksini (FSFI) doldurdular. Sonuçlar premenopozal ve postmenopozal olmak üzere iki grupta yorumlandı. Başlangıç ve tedavi sonrası FSFI skorları önce toplam hasta grubunda ve sonrasında gruplar arası karşılaştırıldı. Bulgular: Solifenasin kullanımı ile orgazm hariç tüm FSFI alt gruplarında belirgin iyileşme gözlenmiştir. Üç aylık (n=110) ve altı aylık (n=65) solifenasin tedavisini takiben ortalama FSFI skorları hem premenopozal hem de postmenopozal hastalarda başlangıca kıyasla önemli ölçüde iyileşmiştir. FSFI skorlarındaki bu iyileşme premenopozal ve postmenopozal gruplar arasında anlamlı farklılık göstermemiştir. Sonuç: Alt üriner sistem semptomları için başlanan solifenasin tedavisinin hem premenopozal hem de postmenopozal kadınların cinsel fonksiyonları üzerinde olumlu bir etkisi olduğu gösterilmiştir. Solifenasin tedavisi kadınlarda cinsel fonksiyonları iyileştirmesine rağmen, bu iyileşme premenopozal ve postmenopozal kadınlar arasında farklılık göstermemiştir.

Anahtar Kelimeler:

Üriner inkontinans, urge; kolinerjik antagonistler; cinsel işlev bozukluğu, fizyolojik

The effect of solifenacin treatment for urge urinary incontinence on sexual function in premenopausal and postmenopausal women: a prospective observational study

Purpose: The aim of this study is to determine whether solifenacin used for urge urinary incontinence improves sexual function and if so this improvement differs between premenopausal and postmenopausal women. Materials and Methods: 120 women, 48 premenopausal and 72 postmenopausal were enrolled in the study. They filled out the Female Sexual Function Index (FSFI) before, three months, and six months after the solifenacin 5mg daily treatment for urge urinary incontinence. The results were interpreted in two groups, premenopausal and postmenopausal. The FSFI scores for baseline and for post-treatment were compared for both groups and with each other. Results: All domains of FSFI except orgasm were improved with the use of Solifenacin. The mean FSFI scores following three months (n=110) and six months (n=65) of solifenacin treatment are significantly improved compared to the baseline in both premenopausal and postmenopausal patients. This improvement in FSFI scores does not significantly differ between premenopausal and postmenopausal groups. Conclusion: Solifenacin treatment for lower urinary tract symptoms has been shown to have a positive impact on the sexual functions of both premenopausal and postmenopausal women. Although treatment with solifenacin improved sexual dysfunction in women, this improvement did not vary between premenopausal and postmenopausal women.

Keywords:

urinary incontinence, sexual dysfunction FSFI, anticholinergic, solifenacin,

PDF

___

Zachariou A, Filiponi M. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function.Int Braz J Urol. 2017;43:713-20.
Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919-24.
Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecol Obstet Invest. 2013;75:46-52.
Dietz, H.P., Subramaniam, N. Is coital incontinence a manifestation of urodynamic stress incontinence or detrusor overactivity? Int Urogynecol J. 2022;33:1175-78.
Luo D, Liu L, Han P, Wei Q, Shen H. Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2012;23:983-91.
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1-20.
Oksuz E, Malhan S. Reliability and validity of the Female Sexual Function Index in Turkish population. Sendrom. 2005;17:54-60.
Batmani S, Jalali R, Mohammadi M, Bokaee S. Prevalence and factors related to urinary incontinence in older adults women worldwide: a comprehensive systematic review and meta-analysis of observational studies. BMC Geriatr. 2021;21:212.
MacLennan AH, Taylor AW, Wilson DH, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG. 2000;107:1460-70.
Sensoy N, Dogan N, Ozek B, Karaaslan L. Urinary incontinence in women: prevalence rates, risk factors and impact on quality of life. Pak J Med Sci. 2013;29:818–22.
Patel UJ, Godecker AL, Giles DL, Brown HW. Updated prevalence of urinary incontinence in women: 2015-2018 national population-based survey data. Female Pelvic Med Reconstr Surg. 2022;28:181-87.
Sinclair AJ, Ramsay IN. The psychosocial impact of urinary incontinence in women. Obstetrician Gynaecologist. 2011;13:143-148.
Hatzichristou D, Kirana PS, Banner L, Althof SE, Lonnee-Hoffmann RA, Dennerstein L et al. Diagnosing sexual dysfunction in men and women: sexual history taking and the role of symptom scales and questionnaires. J Sex Med. 2016;13:1166-82.
Hakimi S, Aminian E, Alizadeh Charandabi SM, Bastani P, Mohammadi M. Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women. Urologia. 2018;85:10-14.
Sacco E, D'Addessi A, Racioppi M, Pinto F, Totaro A, Bassi P. Bladder pain syndrome associated with highest impact on sexual function among women with lower urinary tract symptoms. Int J Gynaecol Obstet. 2012;117:168-72.
Su CC, Sun BY, Jiann BP. Association of urinary incontinence and sexual function in women. Int J Urol. 2015;22:109-13.
Levy G, Lowenstein L. Overactive bladder syndrome treatments and their effect on female sexual function: a review. Sex Med. 2020;8:1-7.
Oh CY, Kim TH, Hwang JW, Bang WJ, Yoo C, Lee YG, Cho JS. 1509 Clinical efficacy of solifenacin on female sexual dysfunction in patients with overactive bladder (sos trial; solifenacin on overactive bladder and sexual dysfunction). J Urol. 2013;189:618-9.
Del Rosso A, Pace G, Di Pierro ED, Masciovecchio S, Galatioto GP, Vicentini C. Impact of overactive bladder on sexual function in women. Urologia. 2011;78:200-2.
Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S et al. The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC Urol. 2018;18:61.
Cakir SS, Degirmentepe RB, Atalay HA, Canat HL, Ozbir S, Culha MG et al. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. Int Urol Nephrol. 2019;51:27-32.
Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol. 2006;195:1730-5.